Abstract
The human p27kip1 gene encodes a cyclin-dependent kinase inhibitor implicated in the negative regulation of the cell cycle. In order to elucidate the possible role of p27 mutations in the development or progression of human breast cancer, we have studied the occurrence of genetic abnormalities in this gene in a series of 30 primary breast carcinomas. Direct sequence analysis of the polymerase chain reaction amplified human p27 gene revealed the occurrence of two sequence variations with respect to the reported sequence; both variants were also present in the lymphocyte DNA from the same patients. First, a silent G to A change at codon 142 (Thr) was detected in a single case. Second, a T to G transversion at codon 109, resulting in a Val to Gly change, was observed in eight tumour DNA samples (26%) and in 31 out of 80 unrelated normal individuals (39%). This latter change creates a BglI restriction site that might be useful for genetic analysis of human tumours. Despite the occurrence of these polymorphisms, we did not however find any evidence of somatic mutations in the coding region of the p27 gene. On the basis of these results, we suggest that alterations in the integrity of the human p27 gene are not common events in human breast carcinomas.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Balbín M, Freije JP, Abrahamson M, Velasco G, Grubb A, López-Otín C (1993) A sequence variation in the human cystatin D gene resulting in an amino acid (Cys/Arg) polymorphism at the protein level. Hum Genet 90:668–669
Caldas C, Hahn SA, Costa LT da, Redston MS, Schutte M, Seymour AB, et al (1994) Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nature Genet 8:27–32
Chedid M, Michieli P, Lengel C, Huppi K, Givol D (1994) A single nucleotide substitution at codon 31 (Ser/Arg) defines a polymorphism in a highly conserved region of the p53-inducible gene WAF1/CIP1. Oncogene 9:3021–3024
El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM et al. (1993) WAF1, a potential mediator of p53 tumor suppression. Cell 75:817–825
Firpo EJ, Koff A, Solomon MJ, Roberts JM (1994) Inactivation of a Cdk2 inhibitor during interleukin 2-induced proliferation of human T lymphocytes. Mol Cell Biol 14:4889–4901
Gu Y, Turck CW, Morgan DO (1993) Inhibition of CDK2 activity in vivo by an associated 20K regulatory subunit. Nature 366:707–710
Guan KL, Jenkins CW, Li Y, Nichols MA, Wu X, O'Keefe CL, Matera AG, Xiong Y (1994) Growth suppression by p 18, a p16INK4/MTSI and p14INK4B/MTS2-related CDK6 inhibitor, correlates with wild-type pRb function. Genes Dev 8:2939–2952
Hannon GJ, Beach D (1994) p15INK4B is a potential effector of TGF-β-induced cell cycle arrest. Nature 371:257–261
Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ (1993) The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75:805–816
Hunter T, Pines J (1994) Cyclins and cancer II: cyclin D and CDK inhibitors come of age. Cell 79:573–582
Kamb A, Shattuck-Eidens D, Eeles R, Liu Q, Gruis A, Ding W, et al. (1994) Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nature Genet 8:22–26
Li YJ, Laurent-Puig P, Salmon RJ, Thomas G, Hamelin R (1995) Polymorphisms and probable lack of mutation in the WAF1CIP1 gene in colorectal cancer. Oncogene 10:599–601
Marchetti A, Buttitta F, Pellegrini S, Bertacca G, Lori A, Bevilacqua G (1995) Absence of somatic mutations in the coding region of the WAF1/CIP1 gene in human breast, lung and ovarian carcinoma: a polymorphism at codon 31. Int J Oncol 6:187–189
Mori T, Miura K, Aoki T, Nishihira T, Mori S, Nakamura Y (1994) Frequent somatic mutation of the MTS1/CDK4I (multiple tumor suppressor/cyclin-dependent kinase 4 inhibitor) gene in esophageal squamous cell carcinoma. Caner Res 54:3396–3397
Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA (1994) Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 368:753–756
Nourse J, Firpo E, Flanagan WM, Coats S, Polyak K, Lee M-H, Massagué J, et al (1994) Interleukin-2-mediated elimination of the p27kip1 cyclin-dependent kinase inhibitor prevented by rapamycin. Nature 372:570–573
Peter M, Herskowitz I (1994) Joining the complex: cyclin-dependent kinase inhibitory proteins and the cell cycle. Cell 79:181–184
Polyak K, Lee M-H, Erdjument-Bromage H, Koff A, Roberts JM, Tempst P, Massagué J (1994a) Cloning of p27Kip1, acyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 78:59–66
Polyak K, Kato J, Solomon MJ, Sherr CJ, Massagué J, Roberts JM, Koff A (1994b) p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-β and contact inhibition to cell cycle arrest. Genes Dev 8:9–22
Serrano M, Hannon GJ, Beach D (1993) A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/ CDK4. Nature 366:704–707
Shiohara M, El-Deiry WS, Wada M, Nakamaki T, Takeuchi S, Yang R, et al (1994) Absence of WAF1 mutations in a variety of human malignancies. Blood 84:3781–3784
Slingerland JM, Hengst L, Pan C-H, Alexander D, Stampfer MR, Reed SI (1994) A novel inhibitor of cyclin-Cdk activity detected in transforming growth factor β-arrested epithelial cells. Mol Cell Biol 14:3683–3694
Spruck CH III, Gonzales-Zulueta M, Shibata A, Simoneau AR, Lin M, Gonzales F, Tsai YC, Jones PJ (1994) p16 gene in uncultured tumours. Nature 370:183–184
Toyoshima H, Hunter T (1994) p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell 78:67–74
Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D (1993) p21 is a universal inhibitor of cyclin kinases. Nature 366:701–704
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ferrando, A.A., Balbín, M., Pendás, A.M. et al. Mutational analysis of the human cyclin-dependent kinase inhibitor p27kip1 in primary breast carcinomas. Hum Genet 97, 91–94 (1996). https://doi.org/10.1007/BF00218840
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF00218840